Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVO-3 randomized trial.

Power, David; Schäfer, Ulrich; Guedeney, Paul; Claessen, Bimmer E; Sartori, Samantha; Sorrentino, Sabato; Lefèvre, Thierry; Kupatt, Christian; Tchetche, Didier; Dumonteil, Nicolas; Webb, John G; Colombo, Antonio; Windecker, Stephan; Ten Berg, Jurriën M; Hildick-Smith, David; Boekstegers, Peter; Linke, Axel; Tron, Christophe; Van Belle, Eric; Asgar, Anita W; ... (2019). Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVO-3 randomized trial. Catheterization and cardiovascular interventions, 93(7), pp. 1374-1381. Wiley-Blackwell 10.1002/ccd.28295

[img] Text
Impact of percutaneous closure device type on vascular and bleeding complications after TAVR.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (978kB) | Request a copy

BACKGROUND/OBJECTIVE Prostar XL (PS) and ProGlide (PG) are common vascular closure devices (VCD) used in TAVR via transfemoral vascular approach. The impact of these VCD on vascular and bleeding complications remains unclear. METHODS The BRAVO-3 trial randomized 802 patients undergoing transfemoral TAVR. We stratified patients according to type of VCD used and examined the 30-day incidence of major or minor vascular complications, major bleeding (BARC ≥3b), AKI and major adverse cardiac and cerebrovascular events (MACCE; death, myocardial infarction or stroke). RESULTS A total of 746 (93%) patients were treated with either PS (n = 352, 47%) or PG (n = 394, 53%) VCD, without significant differences in successful deployment rate (PS 322 [91.2%] vs. PG 373 [94.2%] respectively, p = .20). PG was associated with a significantly lower incidence of major or minor vascular complications, compared to PS (adjusted OR: 0.54; 95% CI: 0.37-0.80; p < .01). Rates of acute kidney injury were also lower with the PG device. There was no significant difference between bleeding, MACCE, and death. CONCLUSIONS Compared to PS, the PG VCD was associated with a lower rate of major or minor vascular complications and lower rates of AKI after transfemoral TAVR.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

UniBE Contributor:

Windecker, Stephan

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1522-1946

Publisher:

Wiley-Blackwell

Language:

English

Submitter:

Nadia Biscozzo

Date Deposited:

13 Feb 2020 08:25

Last Modified:

13 Feb 2020 08:25

Publisher DOI:

10.1002/ccd.28295

PubMed ID:

31116908

Uncontrolled Keywords:

BRAVO TAVR closure device vascular complication

BORIS DOI:

10.7892/boris.139141

URI:

https://boris.unibe.ch/id/eprint/139141

Actions (login required)

Edit item Edit item
Provide Feedback